Tirzepatide costs more on almost every seller this site tracks, and the premium rests on a real average: across trials it takes off more weight than semaglutide does. An average is not a promise to any individual, and the size of the gap between the molecules says nothing about who sits at which end of it.
What happened
The patient started at a body mass index of 39.8 with a HOMA-IR of 5.0, against a reference under 2.0 — insulin resistance well past the threshold. [1] Tirzepatide was escalated to the top dose of 15 mg weekly and held there.
Six months later he had lost under 5%. He was switched to semaglutide 2.4 mg weekly and lost 20% over the following six months, with fasting glucose normalizing, insulin resistance resolving, and appetite control he had not had on the other drug.
What it is good for
Not choosing a molecule. One case cannot do that, and the trial evidence still runs the other way on average.
What it is good for is pricing. Paying a premium for tirzepatide is paying for a higher expected result, and an expectation is not a guarantee that the dearer drug will do anything for a particular person. Sellers do not price that risk and cannot.
What this costs in practice
Six months at a top dose, and on this roster that is rarely the cheap end. The gap between what sellers charge for the two molecules is the number to look at before assuming the premium buys certainty.
It is also the kind of outcome that never appears in a comparison, because a comparison reports a mean. The loser in most published matchups is not even a named product, and a ranking built from those averages is the weakest thing in any table.
What not to do with it
Do not read this as a reason to switch, or as a reason to start on the cheaper molecule to see what happens. Neither follows from one patient.
What follows is narrower and more useful: if an expensive drug at a top dose is doing nothing after six months, that is information, and it is worth taking to whoever is prescribing it rather than escalating the spend.